Cardiovascular and Metabolic Diseases Research Unit and ‡Medicinal Chemistry, Pfizer Worldwide Research and Development , Cambridge, Massachusetts 02139, United States.
Biochemistry. 2013 Dec 23;52(51):9187-201. doi: 10.1021/bi401354d. Epub 2013 Dec 9.
Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Despite a high level of interest in MPO as a therapeutic target, there have been limited reports about MPO inhibitors that are suitable for evaluating MPO in pharmacological studies. 2-Thioxanthine, 3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one (A), has recently been reported to inhibit MPO by covalently modifying the heme prosthetic group. Here we report a detailed mechanistic characterization demonstrating that A possesses all the distinguishing features of a mechanism-based inactivator. A is a time-dependent MPO inhibitor and displays saturable inactivation kinetics consistent with a two-step mechanism of inactivation and a potency (k(inact)/K(I) ratio) of 8450 ± 780 M⁻¹ s⁻¹. MPO inactivation by A is dependent on MPO catalysis and is protected by substrate. A reduces MPO compound I to compound II with a second-order rate constant of (0.801 ± 0.056) × 10⁶ M⁻¹ s⁻¹, and its irreversible inactivation of MPO occurs prior to release of the activated inhibitory species. Despite its relatively high selectivity against a broad panel of more than 100 individual targets, including enzymes, receptors, transporters, and ion channels, we demonstrate that A labels multiple other protein targets in the presence of MPO. By synthesizing an alkyne analogue of A and utilizing click chemistry-activity-based protein profiling, we present that the MPO-activated inhibitory species can diffuse away to covalently modify other proteins, as reflected by the relatively high partition ratio of A, which we determined to be 15.6. This study highlights critical methods that can guide the discovery and development of next-generation MPO inhibitors.
髓过氧化物酶 (MPO) 是一种血红素过氧化物酶,可催化次氯酸的生成。尽管人们对 MPO 作为治疗靶点非常感兴趣,但关于适合用于评估药理学研究中 MPO 的 MPO 抑制剂的报道却很少。2-硫代嘌呤,3-(2-乙氧基丙基)-2-硫代-2,3-二氢-1H-嘌呤-6(9H)-酮(A),最近有报道称其通过共价修饰血红素辅基来抑制 MPO。在这里,我们报告了一项详细的机制特征描述,证明 A 具有所有特征,是一种基于机制的失活剂。A 是一种时间依赖性的 MPO 抑制剂,表现出饱和失活动力学,与两步失活机制一致,效力(k(inact)/K(I) 比值)为 8450 ± 780 M⁻¹ s⁻¹。A 对 MPO 的失活依赖于 MPO 催化,且受底物保护。A 将 MPO 化合物 I 还原为化合物 II 的二级速率常数为(0.801 ± 0.056)× 10⁶ M⁻¹ s⁻¹,其对 MPO 的不可逆失活发生在激活的抑制性物质释放之前。尽管 A 对包括酶、受体、转运体和离子通道在内的 100 多种单个靶标具有相对较高的选择性,但我们证明在 MPO 存在的情况下,A 可标记其他多个蛋白质靶标。通过合成 A 的炔类似物并利用点击化学-活性蛋白质谱分析,我们发现 MPO 激活的抑制性物质可以扩散并与其他蛋白质发生共价修饰,这反映了 A 的相对较高的分配比,我们确定该分配比为 15.6。这项研究突出了可以指导下一代 MPO 抑制剂的发现和开发的关键方法。